Esperion Therapeutics Inc
$ 3.46
2.06%
11 Feb - close price
- Market Cap 810,425,000 USD
- Current Price $ 3.46
- High / Low $ 3.51 / 3.33
- Stock P/E N/A
- Book Value -2.20
- EPS -0.54
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -2.61 %
- 52 Week High 4.17
- 52 Week Low 0.69
About
Esperion Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies to significantly reduce elevated low-density lipoprotein cholesterol (LDL-C). The firm aims to transform cardiovascular disease treatment through its advanced lipid-lowering agents, addressing a critical unmet need in dyslipidemia management. With a robust pipeline and a commitment to patient-centered care, Esperion is strategically positioned to enhance patient outcomes and drive advancements in cardiovascular health. As the company progresses, it stands to substantially influence the future of lipid management therapies in the healthcare landscape.
Analyst Target Price
$6.51
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-13 | 2025-05-05 | 2025-02-25 | 2024-11-05 | 2024-08-12 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-01 | 2023-05-09 | 2023-02-21 |
| Reported EPS | -0.16 | -0.06 | -0.2063 | -0.1013 | -0.15 | -0.33 | 0.34 | -0.5 | -0.37 | -0.46 | -0.79 | -0.76 |
| Estimated EPS | 0.02 | -0.14 | -0.15 | -0.1575 | -0.18 | -0.18 | 0.05 | -0.48 | -0.43 | -0.61 | -0.65 | -0.84 |
| Surprise | -0.18 | 0.08 | -0.0563 | 0.0562 | 0.03 | -0.15 | 0.29 | -0.02 | 0.06 | 0.15 | -0.14 | 0.08 |
| Surprise Percentage | -900% | 57.1429% | -37.5333% | 35.6825% | 16.6667% | -83.3333% | 580% | -4.1667% | 13.9535% | 24.5902% | -21.5385% | 9.5238% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ESPR
2026-02-11 21:28:21
Esperion (NASDAQ: ESPR) announced the grant of 40,200 restricted stock units (RSUs) to 11 newly hired employees under its 2017 Inducement Equity Incentive Plan. This grant, made on February 10, 2026, aligns with NASDAQ Rule 5635(c)(4). The RSUs will vest 25% after one year, with the remaining 75% vesting in twelve equal quarterly installments, contingent on continued employment.
2026-02-07 02:29:21
Esperion Therapeutics is poised for a transformative 2026, driven by a significant upward revision in its quarterly earnings per share forecast from Zacks Research, strong year-over-year revenue growth, and a solid cash position. Key upcoming catalysts include the potential inclusion of bempedoic acid into U.S. treatment guidelines and international expansion, particularly with anticipated revenue from Japan and regulatory decisions in other markets. The company is also pursuing a long-term "Vision 2040" to diversify into rare kidney and liver diseases, with investors awaiting final audited financial results for Q4 and full-year 2025.
2026-02-05 13:28:26
Zacks Research significantly increased its Q4 2025 EPS estimate for Esperion Therapeutics (NASDAQ:ESPR) to $0.32, up from $0.02, and issued optimistic forecasts for 2026-2027, signaling a potential path to profitability. Despite some mixed analyst sentiment, the company holds a "Moderate Buy" consensus rating with an average price target of $7.20. Esperion Therapeutics' stock currently trades around $3.42, and institutions own approximately 47% of its shares.
2026-02-04 12:29:21
Zacks Research has lowered its Q3 2026 earnings per share estimate for Esperion Therapeutics (NASDAQ:ESPR) to $0.01 from $0.04, and projects FY2027 EPS of $0.26. This adjustment comes despite Esperion recently beating revenue expectations but missing EPS estimates in its last quarterly report. The biopharmaceutical company currently holds a "Moderate Buy" consensus rating with an average price target of $7.20.
2026-01-31 07:32:00
Wall Street Zen upgraded Esperion Therapeutics (NASDAQ:ESPR) from a "hold" to a "buy" rating, reflecting a "Moderate Buy" consensus from analysts with an average price target of $7.20. Despite missing EPS estimates, the biopharmaceutical company beat revenue expectations. Insider selling and institutional investment details were also reported, with institutional investors owning approximately 47.4% of the company.
2026-01-24 08:58:16
AIGH Capital Management LLC recently purchased 3,000,000 shares of Esperion Therapeutics (ESPR) for approximately $7.95 million, making it a significant holding in their portfolio. This investment positions AIGH Capital Management as a notable owner of Esperion, a biopharmaceutical company focused on cardiovascular disease therapies. Despite some insider selling, analysts maintain a "Moderate Buy" rating for ESPR, projecting potential upside from its current trading price.
